[Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options for 30,000 shares of common stock at an exercise price of $10.42 per share and then sold 30,000 shares in open-market transactions on the same date.

The sales were executed in two tranches at weighted-average prices of $50.4454 and $51.0150 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. Following these transactions, he reported direct ownership of 0 common shares and 267,407 options remaining from the underlying award, which continues to vest monthly through October 2027.

Insights

Insider transactions analyst

Routine option exercise and pre-planned sale totaling 30,000 shares.

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised options covering 30,000 shares at an exercise price of $10.42 and sold the resulting 30,000 shares in open-market trades on March 10, 2026.

The filing shows weighted-average sale prices of $50.4454 and $51.0150, with prices in each tranche spread over narrow ranges. A footnote states the transactions were made under a Rule 10b5-1 trading plan adopted on September 29, 2025, indicating they were pre-scheduled rather than opportunistic.

After the transactions, Bernstein reported 0 directly held common shares but 267,407 options remaining from this award, which vested or vests monthly after an initial one-quarter cliff. This pattern is characteristic of an exercise-and-sell for liquidity while retaining substantial derivative exposure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bernstein Harold

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D & CMO

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		M(1)		30,000	A	$10.42	30,000	D
Common Stock	03/10/2026		S(1)		29,652	D	$50.4454(2)	348	D
Common Stock	03/10/2026		S(1)		348	D	$51.015(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.42	03/10/2026		M(1)			30,000	(4)	10/26/2032	Common Stock	30,000	$0	267,407	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.09 per share, inclusive.

4. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Maze Therapeutics (MAZE) executive Harold Bernstein do in this Form 4?

Harold Bernstein exercised stock options for 30,000 Maze Therapeutics shares, then sold all 30,000 shares in open-market transactions. The activity reflects an option exercise followed by a complete sale of the acquired shares on the same date.

At what prices were Maze Therapeutics (MAZE) shares sold in the reported transactions?

The Form 4 reports weighted-average sale prices of $50.4454 and $51.0150 per share. Footnotes explain these averages cover multiple trades in narrow ranges between $50.00–$50.99 and $51.00–$51.09 per share, respectively.

Were the Maze Therapeutics (MAZE) insider sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted by Harold Bernstein on September 29, 2025. Such plans pre-schedule trades, indicating the timing was arranged in advance rather than based on short-term market moves.

How many Maze Therapeutics (MAZE) options does Harold Bernstein hold after these transactions?

After exercising 30,000 options, Bernstein reported 267,407 options remaining from the same award. The option initially vested 25% on October 3, 2023, and then in equal monthly installments, subject to his continued service with Maze Therapeutics.

Does Harold Bernstein still hold Maze Therapeutics (MAZE) common stock after this Form 4?

Following the reported sales, Bernstein listed direct ownership of 0 Maze Therapeutics common shares. However, he continues to hold a substantial option position, with 267,407 options remaining from the underlying equity award.